Mira PharmaceuticalsMIRA +0.74%13 3-Year ROIIC % is 468.71 as of Dec. 2025, which is 28% below its 10-year median of 651.57. GuruFocus rates MIRA with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 944 Drug Manufacturers companies, Mira Pharmaceuticals ranks better than 97.46% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Mira Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 468.71%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Mira Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
MIRA's 3-Year ROIIC % is ranked better than 97.46% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs MIRA: 468.71
Mira Pharmaceuticals (NAS:MIRA) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Mira Pharmaceuticals 3-Year ROIIC % Related Terms
Mira Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Mira Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIRA vs NSRX, SCLX, MDCX: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mira Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Mira Pharmaceuticals's 3-Year ROIIC % falls into.
Mira Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -10.493 (Dec. 2025) - -7.048 (Dec. 2022) )
/
( 0.036 (Dec. 2025) - 0.771 (Dec. 2022) )
=
-3.445
/
-0.735
=
468.71%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Mira Pharmaceuticals (MIRA) has a 3-Year ROIIC % of 468.71 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mira Pharmaceuticals and its competitors. This is 28% below median its historical median of 651.57. Over the past decade, Mira Pharmaceuticals' 3-Year ROIIC % has ranged from 468.71 to 834.42. According to the industry distribution chart, Mira Pharmaceuticals ranks #24 out of 944 companies in the Drug Manufacturers industry, placing it in the top 2.5%.
Is Mira Pharmaceuticals' 3-Year ROIIC % too high?
Mira Pharmaceuticals' current 3-Year ROIIC % of 468.71 is 28% below median its 10-year median of 651.57. Over the past 10 years, this metric has ranged from a low of 468.71 to a high of 834.42. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Mira Pharmaceuticals' value of 468.71 is 12794.4% above this industry median. Based on the distribution chart, Mira Pharmaceuticals ranks #24 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' 3-Year ROIIC % compare to NSRX and SCLX?
According to the Drug Manufacturers industry distribution chart, Mira Pharmaceuticals ranks #24 out of 944 companies for 3-Year ROIIC %. This places Mira Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.64. Mira Pharmaceuticals' value of 468.71 is 12794.4% above this benchmark. Historically, Mira Pharmaceuticals' own 3-Year ROIIC % has ranged from 468.71 to 834.42 over the past decade. While the company's 10-year median is 651.57 vs. the industry median of 3.64, Mira Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mira Pharmaceuticals's current 3-Year ROIIC % of 468.71 is 12794.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mira Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mira Pharmaceuticals's current 3-Year ROIIC % is 468.71, which is 28% below median its own 10-year median of 651.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current 3-Year ROIIC % of 468.71. The current 3-Year ROIIC % is 468.71, which is 28% below median its 10-year median of 651.57 and 12794.4% above the Drug Manufacturers industry median of 3.64. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current 3-Year ROIIC % is 468.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
13GF Score
Get the complete analysis for MIRA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIRA has been successfully added to your 
